医者への秘密の製薬会社の支払は48の州に法的に残る

によって デイヴィッドGutierrez

医者に作る要求し、これらの司法権で均等になる薬品会社のレポートのギフト5つの州そしてコロンビア特別区だけこれらのトランザクションの細部が事実上の秘密に残る法律がで出版される調査に従ってそう不完全に実施される アメリカ医学連合のジャーナル.

Researchers examined public records from Vermont and Minnesota, the only two states that require disclosure by pharmaceutical companies and make that data available to the public. By studying the data from 2002 to 2004, the researchers hoped to gain a better understanding of how money moves from the pharmaceutical to the medical industry.

“What we really found was laws aren’t working,” said study author Joseph Ross, of the geriatrics department of Mount Sinai School of Medicine in New York.

The researchers found that while reported payments were quite high, the details of those transactions were not available. In other cases, reported payments were so low as to be suspicious. For example, GlaxoSmithKline claimed zero dollars spent in Vermont in the time period studied, yet the state attorney general listed the company as making more payments than any other. In Minnesota, Amgen recorded zero dollars in payments in 2002 or 2004, but more than $4 million in 2003.

Part of the reason for this inconsistency is that gifts of drugs or items not yet on the market can be classified as “trade secrets” and not reported. But Ross believes that this loophole is being exploited.

“To designate every payment made as a trade secret … seems improbable,” he said.

Pharmaceutical companies have been known to give doctors extravagant gifts including all-expense-paid vacations or gourmet dinners as part of their marketing campaigns. According to Dr. Harlan Krumholz, an associate professor at the Yale University School of Medicine, this presents a conflict of interest that the public should know about.

Ross agrees. “If both parties think this payment is appropriate, then this information should be made available to the public,” he said.

Comment on 'Secret drug company payments to doctors remain legal in 48 states' :

RSS TrackBack URL

Related News: